Status:
RECRUITING
Prevention of Neuropathic Pain From Oxaliplatin by Photobiomodulation
Lead Sponsor:
Saint-Gregoire Private Hospital Center
Conditions:
Cancer of the Gastrointestinal Tract
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Peripheral neuropathy is one of the most common side effects of oxaliplatin (OXA)-based chemotherapy for patients treated for digestive cancers, disabling and dose-limiting. Several strategies have be...
Eligibility Criteria
Inclusion
- Recent diagnosis of digestive cancer
- 12 planned cycles of oxaliplatin
- Ability to understand and willingness to sign an informed consent form before starting any study procedures
- Patient benefiting from French health insurance
Exclusion
- History of neuropathy before the start of the study,
- Symptomatic treatment of pain (or neuropathic pain),
- Patient with a psychotic disorder,
- Patient with diabetic neuropathy,
- Patient with metastatic cancer
- Patient with renal insufficiency,
- Adults under guardianship or curatorship,
- Vulnerable people
Key Trial Info
Start Date :
May 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06199115
Start Date
May 31 2023
End Date
April 1 2025
Last Update
January 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHP Saint-Grégoire
Saint-Grégoire, France, 35700